| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Biology and Genetics |
Institute for Cancer Research and Treatment (I.R.C.C.), University of Torino School of Medicine, 10060 Candiolo (TO), Italy
In epithelial cells, hepatocyte growth factor (HGF) activates a genetic program involving cell-cell dissociation ("scattering"), growth and invasiveness. The full program is not elicited by other growth factors like epidermal growth factor, and is aberrantly activated during cancer progression to the invasive-metastatic phenotype. To identify genes involved in the onset of invasive growth, we explored by cDNA microarrays the in vitro transcriptional response to HGF of mouse embryo liver cells. We identified osteopontin (OPN), a secreted matrix protein, as a major HGF transcriptional target. The wave of OPN induction is maximal at 6 h, in concomitance with the initiation of scattering, and is specific, because no other matrix protein among those explored by the microarray is affected. Interestingly, HGF, but not epidermal growth factor, promotes cell adhesion to OPN via the CD44 receptor. Scattering is significantly impaired by antibodies against OPN and CD44; conversely, constitutive OPN overexpression dramatically increases the motile and invasive responses to HGF, leading to disruption of the ordered morphogenetic program triggered by this ligand.
This article has been cited by other articles:
![]() |
S. Arena, C. Isella, M. Martini, A. de Marco, E. Medico, and A. Bardelli Knock-in of Oncogenic Kras Does Not Transform Mouse Somatic Cells But Triggers a Transcriptional Response that Classifies Human Cancers Cancer Res., September 15, 2007; 67(18): 8468 - 8476. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Cheng, D.-H. Huo, D.-M. Kuang, J. Yang, L. Zheng, and S.-M. Zhuang Human Macrophages Promote the Motility and Invasiveness of Osteopontin-Knockdown Tumor Cells Cancer Res., June 1, 2007; 67(11): 5141 - 5147. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Schapira, G. Lazer, and S. Katzav Osteopontin Is an Oncogenic Vav1- but not Wild-type Vav1-Responsive Gene: Implications for Fibroblast Transformation. Cancer Res., June 15, 2006; 66(12): 6183 - 6191. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Vietor, R. Kurzbauer, G. Brosch, and L. A. Huber TIS7 Regulation of the {beta}-Catenin/Tcf-4 Target Gene Osteopontin (OPN) Is Histone Deacetylase-dependent J. Biol. Chem., December 2, 2005; 280(48): 39795 - 39801. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Celetti, D. Testa, S. Staibano, F. Merolla, V. Guarino, M. D. Castellone, R. Iovine, G. Mansueto, P. Somma, G. De Rosa, et al. Overexpression of the Cytokine Osteopontin Identifies Aggressive Laryngeal Squamous Cell Carcinomas and Enhances Carcinoma Cell Proliferation and Invasiveness Clin. Cancer Res., November 15, 2005; 11(22): 8019 - 8027. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Guarino, P. Faviana, G. Salvatore, M. D. Castellone, A. M. Cirafici, V. De Falco, A. Celetti, R. Giannini, F. Basolo, R. M. Melillo, et al. Osteopontin Is Overexpressed in Human Papillary Thyroid Carcinomas and Enhances Thyroid Carcinoma Cell Invasiveness J. Clin. Endocrinol. Metab., September 1, 2005; 90(9): 5270 - 5278. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. K. Borg It's the Matrix!: ECM, Proteases, and Cancer Am. J. Pathol., April 1, 2004; 164(4): 1141 - 1142. [Full Text] [PDF] |
||||
![]() |
C.-G. Huh, V. M. Factor, A. Sanchez, K. Uchida, E. A. Conner, and S. S. Thorgeirsson Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair PNAS, March 30, 2004; 101(13): 4477 - 4482. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Gao, H. Guo, L. Downey, C. Marroquin, J. Wei, and P. C. Kuo Osteopontin-dependent CD44v6 expression and cell adhesion in HepG2 cells Carcinogenesis, December 1, 2003; 24(12): 1871 - 1878. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Orian-Rousseau, L. Chen, J. P. Sleeman, P. Herrlich, and H. Ponta CD44 is required for two consecutive steps in HGF/c-Met signaling Genes & Dev., December 1, 2002; 16(23): 3074 - 3086. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |